CRP and cancer: Among STEMI patients, higher C-reactive protein, higher platelet counts, and lower hemoglobin were significantly associated with cancer incidence during the first year after STEMI (Fig. 2; age- and sex-adjusted HRs 2.93 for C-reactive protein > 10 mg/dL, 2.10 for platelet count > 300*109, and 3.92 for hemoglobin < 7.5 mmol/L).